TOKYO -- Japan's Fujifilm Holdings said Monday that it has won an order to produce a key component of American biotechnology company Novavax's coronavirus vaccine candidate at a site in the U.K.
Fujifilm subsidiary Fujifilm Diosynth Biotechnologies will churn out the antigen component starting in early 2021. The output will fulfill an order by the British government for 60 million doses.
